Prognostic factors in patients with advanced neuroendocrine neoplasia treated with radiopeptides (PRRT) - Data from the national registry SEPTRALU

被引：0
|
作者：
Bello, P. [1 ]
Mitjavila Casanovas, M. [2 ]
Jimenez-Fonseca, P. [3 ]
Cabezas Agricola, J. M. [4 ]
Hernando Cubero, J. [5 ]
Garcia Canamaque, L. [6 ]
Gajate, P. [7 ]
Riesco, M. C. [8 ]
Custodio, A. [1 ,9 ]
Miguel Martinez, M. B. [10 ]
Balaguer, D. [11 ]
Carmona-Bayonas, A. [12 ]
机构：
[1] Hosp Univ La Fe, Dept Nucl Med, Valencia, Spain
[2] Hosp Univ Puerta Hierro, Dept Nucl Med, Madrid, Spain
[3] Hosp Univ Cent Asturias, Dept Med Oncol, Oviedo, Spain
[4] Hosp Univ Santiago Compostela, Santiago De Compostela, Spain
[5] Hosp Univ Val dHebron, Barcelona, Spain
[6] Hosp HM Sanchinarro, Madrid, Spain
[7] Hosp Univ Ramon y Cajal, Madrid, Spain
[8] Hosp Univ Doce Octubre, Madrid, Spain
[9] Hosp Univ La Paz, Madrid, Spain
[10] Hosp Univ Burgos, Burgos, Spain
[11] Hosp Univ Doctor Peset, Valencia, Spain
[12] UMU, Hosp Univ Morales Meseguer, Hematol & Med Oncol Dept, IMIB, Murcia, Spain
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2023年 / 35卷
关键词：
177lu-dotatate; neuroendocrine tumor; prrt; prognosis; radionuclide therapy; survival;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H05
引用
收藏
页码：177 / 177
页数：1
相关论文
共 50 条
  • [1] Prognostic factors in 382 patients treated with 177-Lu-DOTATATE: Data from the SEPTRALU registry
    Pubul, V
    Bello, P.
    Hernando, J.
    Rodeno, E.
    Gajate, P.
    Marin, D.
    Garcia-Canamaque, L.
    Cano, J. M.
    Repetto, A.
    Jimenez-Fonseca, P.
    Carmona-Bayonas, A.
    Mitjavila Casanovas, M.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 80 - 80
  • [2] PRRT of 200 patients from the SEPTRALU registry: real-world data
    Mitjavila Casanovas, M.
    Carmona Bayonas, A.
    Bello, P.
    Pubul, V.
    Garcia-Canamaque, L.
    Arbizu, J.
    Rotger, A.
    Llana, B.
    Navarro, T.
    Castellon, M.
    Field, C.
    Estorch, M.
    Riesco, C.
    Teule, A.
    Muro, M.
    Garcia-Alonso, P.
    Repetto, A.
    Miguel, M.
    Caballero, E.
    Navarro, M.
    Aller, J.
    del Olmo, M.
    Blanco, C.
    Jimenez-Fonseca, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S86 - S87
  • [3] 177Lu-DOTATATE therapy in advanced pancreatic neuroendocrine tumors: data from 187 patients of the national registry SEPTRALU
    Mitjavila-Casanovas, M.
    Bello, P.
    Pubul, V.
    Garcia-Burillo, A.
    Hernando, J.
    Alonso-Farto, J.
    Arbizu, J.
    Rodeno, E.
    Estorch, M.
    Gajate, P.
    Marin, D.
    Garcia-Canamaque, L.
    Llana, B.
    Miguel, B.
    Castellon, M.
    Caballero, E.
    Coronado, M.
    Cano, J.
    Repetto, A.
    Vercher, J.
    Muros, A.
    Garcia-Alonso, P.
    del Olmo, M.
    Carmona-Bayonas, A.
    Jimenez-Fonseca, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S247 - S247
  • [4] Retreatment with peptide receptor radionuclide therapy (PRRT) in patients (p) with neuroendocrine tumors (NET): Spanish clinical experience from SEPTRALU national registry
    Hernando Cubero, J.
    Lago, N. Martinez
    Mitjavila, M.
    Garcia-Burillo, A.
    Pubul, V.
    Bello, P.
    Cano, J. M.
    Llana, B.
    Castellon, M.
    Rodeno, E.
    Pineiro, A.
    Soldevilla, C.
    Nevares, M.
    Aller, J.
    Anido Herranz, U.
    Carnero Lopez, B.
    Nogareda, Z.
    Garcia Alvarez, A.
    Jimenez Fonseca, P.
    Capdevila Castillon, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S756 - S756
  • [5] Patients with Advanced Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy with 177Lu-DOTATE: Data from Spanish SEPTRALU Registry
    Mitjavila, M.
    Percovich, J. C.
    Pombo Pasin, M. C.
    Bello, P.
    Arbizu, J.
    Llana, B.
    Riesco, M. C.
    Muros, M. A.
    Estenoz, J.
    Rotger, A.
    Aller, J.
    Jimenez-Fonseca, P.
    NEUROENDOCRINOLOGY, 2019, 108 : 223 - 223
  • [6] 177Lu-DOTATATE in advanced neuroendocrine tumours: real word data from SEPTRALU registry
    Mitjavila Casanovas, M.
    Field, C.
    Bello, P.
    Nogareda Seoane, Z.
    Garcia-Canamaque, L.
    Arbizu, J.
    Rotger, A.
    Gajate, P.
    Castellon, M.
    Muros, M.
    Teule, A.
    Repetto, A.
    Miguel Martinez, M.
    Estorch, M.
    Jimenez Fonseca, P.
    Carmona-Bayona, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S93 - S93
  • [7] 177Lu-DOTATATE in advanced neuroendocrine neoplasms of different locations - Data from 552 cases in the SEPTRALU registry
    Mitjavila Casanovas, M.
    Carmona-Bayonas, A.
    Bello, P.
    de Matias Leralta, J. M.
    Garcia Burillo, A.
    Percovich, J. C.
    Arbizu, J.
    Estorch, M.
    Llana, B.
    Rodeno, E.
    Castellon, M.
    Jimenez-Fonseca, P.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 200 - 200
  • [8] SEPTRALU registry of 177-Lu-DOTATATE in neuroendocrine tumors: Data from 321 patients in clinical practice
    Mitjavila Casanovas, M.
    Bello, P.
    Pubul, V
    Arbizu, J.
    Gajate, P.
    Riesco-Martinez, M. C.
    Percovich, J. C.
    Garcia Canamaque, L.
    Castellon, M.
    Llana, B.
    Jimenez-Fonseca, P.
    Carmona-Bayonas, A.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 191 - 191
  • [9] 177-Lu-DOTATATE in 200 Patients with Neuroendocrine Tumors: Real-World Data from the SEPTRALU Registry
    Carmona-Bayonas, A.
    Mitjavila, Casanovas M.
    Bello, P.
    Percovich, J. C.
    Prieto, A.
    Arbizu, J.
    Field, C.
    Muro, M. A.
    Del Olmo, M. C.
    Castellon, M.
    Pubul, V
    Jimenez-Fonseca, P.
    NEUROENDOCRINOLOGY, 2020, 110 : 251 - 251
  • [10] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE (177Lu) Is Effective and Safe in Patients with Pretreated Metastatic Neuroendocrine Tumors: Data from Spanish SEPTRALU Registry
    Bello, P.
    Jimenez-Fonseca, P.
    Percovich, J. C.
    Anido Herranz, U.
    Gajate, P.
    Castellon, M.
    Estorch, M.
    Gonzalez, E.
    Field, C.
    Garcia Alonso, P.
    Carmona-Bayonas, A.
    Mitjavila, M.
    NEUROENDOCRINOLOGY, 2019, 108 : 198 - 198
12345